We are at a pivotal moment in the renaissance of psychedelics, with the industry as a whole seeing a vast number of differentiated drug discovery, clinical trial, regulatory, and intellectual property milestones reached in the first half of 2021. Today, we’ve brought together the following experts in IP, clinical trials, and drug discovery to discuss the current state of the psychedelic industry…


Previous articleEntheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave
Next articlePsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie